간행물

대한간암학회> 대한간암학회지

대한간암학회지 update

Journal of liver cancer

  • : 대한간암학회
  • : 의약학분야  >  내과학
  • : KCI등재
  • :
  • : 연속간행물
  • : 반년간
  • : 2288-8128
  • : 2283-5001
  • : 대한간암연구회지(~2010)→대한간암연구학회지(2011~)

수록정보
수록범위 : 1권0호(2001)~18권2호(2018) |수록논문 수 : 456
대한간암학회지
18권2호(2018년 09월) 수록논문
최근 권호 논문
| | | |

KCI등재

1강력한 항바이러스 치료가 보편적으로 가능한 시대에서 만성 B형간염 환자의 간암 발생 예측 모델

저자 : 이혜원 ( Hye Won Lee ) , 김범경 ( Beom Kyung Kim )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 18권 2호 발행 연도 : 2018 페이지 : pp. 87-93 (7 pages)

다운로드

(기관인증 필요)

초록보기

Appropriate prediction of hepatocellular carcinoma (HCC) development is of paramount importance in terms of decision on antiviral therapy and HCC surveillance. To date, many HCC risk prediction models had been derived based on well-known risk factors such as age, male gender, the degree of fibrosis, and serum hepatitis B virus (HBV)-DNA load. Overall, such models showed high negative predictive values of approximately >90%, excluding the possibility of HCC development in 3 to 10 years with considerable accuracy. On the other hands, on the basis that potent antiviral therapy can substantially reduce the risk of HCC, its indications are steadily getting expanded for prevention of disease progression. Since antiviral therapy is a very strong disease modifier, the uniform application of HCC risk scores developed before the era of potent antiviral therapy would overestimate the risk of HCC. Furthermore, the tools to assess the fibrotic burden have remarkably evolved, from subjective determination based upon clinical symptom sign and ultrasonographic finding to more objective and delicate non-invasive tests based upon imaging and/or serological methods. Therefore, in the current era of potent antiviral therapy, the clinical significance of recently developed HCC risk models for patients with chronic HBV infection should be reappraised further. (J Liver Cancer 2018;18:87-93)

KCI등재

2간세포암종에서의 체부정위방사선치료

저자 : 정진홍 ( Jinhong Jung ) , 윤상민 ( Sang Min Yoon )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 18권 2호 발행 연도 : 2018 페이지 : pp. 94-102 (9 pages)

다운로드

(기관인증 필요)

초록보기

With recent remarkable technological advances in radiation therapy, stereotactic body radiation therapy (SBRT) is regarded as an alternative treatment option for hepatocellular carcinoma (HCC) that is not suitable for curative treatment. Several prospective and retrospective studies on the use of SBRT in patients with HCC showed promising results. Furthermore, on-going prospective studies are examining the role of SBRT as a single ablative modality or a combination treatment in patients with HCC. Here, we summarize previous studies and recent updates and discuss the future perspectives of SBRT for HCC. (J Liver Cancer 2018;18:94-102)

KCI등재

3고령 환자의 간암치료 및 감시

저자 : 노승윤 ( Seoung Yoon Rho ) , 이현웅 ( Hyun Woong Lee ) , 김경식 ( Kyung Sik Kim )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 18권 2호 발행 연도 : 2018 페이지 : pp. 103-114 (12 pages)

다운로드

(기관인증 필요)

초록보기

Hepatocellular carcinoma (HCC) is the third most common cancer in the digestive system based on survey of domestic cancer incidence, and the ratio of elderly aged 65 or older is expected to rise steadily, leading to a higher incidence of total hepatocellular carcinoma. The most important thing in treating these older patients with HCC is to assess the benefits and risks of the treatment in advance. In other words, the benefit of treatment should be greater than the reduction of survival period or maladjustment due to treatment. Based on these perspectives, we examined how the detailed treatment of hepatocellular carcinoma differs from that of general treatment in elderly patients. In conclusion, older age was not a definite prognostic factor of survival risk-benefit comparison in the most treatment modalities. However it should be carefully considered and approached about possible complications in treating HCC in elderly patients. (J Liver Cancer 2018;18:103-114)

KCI등재

4절제연 양성의 간내담관암에서 수술 후 항암화학방사선치료의 역할

저자 : 김경수 ( Kyung Su Kim ) , 김휘영 ( Hwi Young Kim ) , 김규보 ( Kyubo Kim ) , 이남준 ( Nam-joon Yi ) , 서경석 ( Kyung-suk Suh ) , 지의규 ( Eui Kyu Chie )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 18권 2호 발행 연도 : 2018 페이지 : pp. 115-120 (6 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: To investigative the potential role of postoperative chemoradiotherapy (CCRT) after R1 resection of intrahepatic cholangiocarcinoma (IHCC).
Methods: Between January 2000 and December 2012, medical records of 18 patients who underwent curative surgery with R1 resection for IHCC were retrospectively reviewed.
Results: Median age was 68 years and 12 patients (66.7%) were male. Median tumor size was 5.0 cm (range, 2.2-11.0) and 12 patients (66.7%) had T3 or higher disease. Lymph nodes were involved in four patients (22.2%). Vascular invasion and perineural invasion were present in 10 (55.6%) and 12 patients (66.7%), respectively. Postoperative CCRT given with 5-fluorouracil or gemcitabine were delivered to 7 patients (38.9%). Median radiation dose was 50.4 Gy (range, 45-54). Univariate analysis showed that median loco-regional recurrence-free survival (LRRFS), progression-free survival (PFS) and overall survival (OS) were prolonged for patients treated with CCRT (median LRRFS; 5.6 months vs. not reached, P<0.001, median PFS; 5.6 vs. 8.3 months, P=0.047, median OS; 15.0 vs. 26.6 months, P=0.064).
Conclusions: Postoperative CCRT improved the loco-regional control and PFS in IHCC patients with R1 resection. Further study is warranted to validate the role of postoperative CCRT for these patients. (J Liver Cancer 2018;18:115-120)

KCI등재

5고빌리루빈혈증과 담도 침범을 동반한 간세포암에 대한 경동맥화학 리피오돌색전술의 안전성과 예후 인자

저자 : 양경모 ( Keungmo Yang ) , 성필수 ( Pil Soo Sung ) , 오정석 ( Jung Suk Oh ) , 천호종 ( Ho Jong Chun ) , 장정원 ( Jeong Won Jang ) , 배시현 ( Si Hyun Bae ) , 최종영 ( Jong Young Choi ) , 윤승규 ( Seung Kew Yoon )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 18권 2호 발행 연도 : 2018 페이지 : pp. 121-129 (9 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: The treatments and outcomes of hepatocellular carcinoma (HCC) with bile duct invasion are not well known. We aimed to confirm the safety of transarterial chemolipiodolization (TACL) and identify prognostic factors for patients with bile duct invasion treated with TACL.
Methods: Fifty patients with central bile duct invasion treated with TACL between 2005 and 2017 were enrolled. Patients were divided into three groups: hyperbilirubinemia (total bilirubin ≥2.5 mg/dL) with pre-TACL biliary drainage, hyperbilirubinemia without biliary drainage, and without hyperbilirubinemia. Tumor response to TACL, survival outcomes, length of hospitalization, adverse events using Common Terminology Criteria for Adverse Events (CTCAE), and factors affecting overall survival were compared.
Results: TACL-induced changes of mean CTCAE grades for albumin, alanine aminotransferase, creatinine, prothrombin time, and platelet were not significantly different among patients with or without initial hyperbilirubinemia. Serum bilirubin level was not significantly changed after TACL in all the three groups. Overall survival was not significantly different among the three groups (P=0.097). On multivariate analysis, alpha-fetoprotein <400 ng/dL (hazard ratio [HR]=0.477, P=0.048) and highest total bilirubin level of <2.5 mg/dL within one month after TACL (HR=0.335, P=0.004) were significantly associated with longer survival.
Conclusions: TACL was a safe treatment for HCC patients with central bile duct invasion, irrespective of the presence of initial hyperbilirubinemia. (J Liver Cancer 2018;18:121-129)

KCI등재

6주요간문맥종양혈전을 동반한 간세포암에 대한 다기관 체부정위방사선치료계획 비교연구(KROG 16-17)

저자 : 배선현 ( Sun Hyun Bae ) , 김미숙 ( Mi-sook Kim ) , 장원일 ( Won Il Jang ) , 김진호 ( Jin Ho Kim ) , 김우철 ( Woo Chul Kim ) , 김진희 ( Jin Hee Kim ) , 정배권 ( Bae-kwon Jeong ) , 김용호 ( Yong Ho Kim ) , 조선미 ( Sunmi Jo ) , 최철원 ( Chul Won Choi ) , 박영희 ( Younghee Park ) , 조광환 ( Kwa

발행기관 : 대한간암학회 간행물 : 대한간암학회지 18권 2호 발행 연도 : 2018 페이지 : pp. 130-141 (12 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: To evaluate the technical feasibility of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC) with the major portal vein tumor thrombosis (PVTT).
Methods: Ten institutions affiliated with the Korean Stereotactic Radiosurgery Group were provided the contours of four cases: the first case was the first branch PVTT with sufficient normal liver volume (NLV), the second was the first branch PVTT with insufficient NLV, the third was the main trunk PVTT at confluence level, and the fourth was the main trunk PVTT with entire length. The institutions were asked to make SBRT plans according to their current treatment protocols and to complete facility questionnaires.
Results: Based on institutional protocols, SBRT was feasible in nine institutions for the first case (32-60 Gy in 3-5 fractions), in eight institutions for the second case (32-50 Gy in 3-5 fractions), in seven institutions for the third case (35-60 Gy in 3-5 fractions), and in four institutions for the fourth case (35-42 Gy in 4-5 fractions). The other institutions recommended hypo- or conventional fractionation due to insufficient NLV or gastrointestinal organ proximity. With analysis of the SBRT dose to the central hepatobiliary tract, the major PVTT could theoretically be associated with a high risk of hepatobiliary toxicity.
Conclusions: Although SBRT is a technically feasible option for HCC with the major PVTT, there was a variability among the participating institutions. Therefore, further studies will be necessary to standardize the practice of SBRT for the major PVTT. (J Liver Cancer 2018;18:130-141)

KCI등재

7우심방 전체를 침범한 진행성 간세포암종에서의 소라페닙 치료

저자 : 강영모 ( Young Mo Kang ) , 류수형 ( Soo Hyung Ryu ) , 이보경 ( Bo Kyung Lee ) , 고경호 ( Kyoung Ho Ko ) , 박태영 ( Tae Young Park ) , 문정섭 ( Jeong Seop Moon ) , 조선화 ( Seon Hwa Cho )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 18권 2호 발행 연도 : 2018 페이지 : pp. 142-145 (4 pages)

다운로드

(기관인증 필요)

초록보기

Advanced hepatocellular carcinoma (HCC) with tumor thrombus extending through the hepatic veins, inferior vena cava, and right atrium (RA) is very rare. However, whether active treatments such as radiation, transcatheter arterial chemoembolization, and sorafenib in advanced HCC with RA involvement prolong survival is uncertain. We present a rare case of advanced HCC with tumor thrombus nearly occupying the entire RA that was treated with sorafenib. The patient received 400 mg sorafenib twice daily. However, her liver enzyme levels continued to increase and abdominal computed tomography showed an increase in the tumor size in the liver and RA. In the present case, active treatment with sorafenib was ineffective; thus, palliative care may be more beneficial in advanced HCC with extensive RA involvement. (J Liver Cancer 2018;18:142-145)

KCI등재

8초고령의 환자에서 자연경과를 관찰한 간세포암종 1예

저자 : 박유민 ( Yoo Min Park ) , 최인주 ( In Zoo Choi ) , 심재준 ( Jae-jun Shim ) , 김병호 ( Byung-ho Kim )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 18권 2호 발행 연도 : 2018 페이지 : pp. 146-150 (5 pages)

다운로드

(기관인증 필요)

초록보기

As the mean life expectancy increases, the incidence of hepatocellular carcinoma (HCC) in superelderly patients (>85 years old) is expected to increase in Korea. However, their clinical features, treatments, and treatment outcomes are unclear. Herein, we present a case of a large single HCC and its natural course in an 86-year-old man who refused any treatment following histologic diagnosis. (J Liver Cancer 2018;18:146-150)

KCI등재

9다발성 전이를 동반한 고령의 간세포암 환자에서 경동맥방사선색전술과 반복적 경동맥화학색전술로 간내암과 다발성 전이의 부분관해를 이룬 증례

저자 : 황상연 ( Sang Youn Hwang ) , 이선미 ( Seon-mi Lee ) , 임정우 ( Jung Woo Im ) , 전기정 ( Ki Jeong Jeon ) , 안상부 ( Sang Bu Ahn ) , 박진영 ( Jin-young Park )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 18권 2호 발행 연도 : 2018 페이지 : pp. 151-156 (6 pages)

다운로드

(기관인증 필요)

초록보기

The number of older adults with hepatocelluar carcinoma (HCC) has been increasing with longer life expectancy and earlier diagnosis and treatment. However, older patients have lesser function reserve of multiple organ systems, more disability rate. Therefore, the treatment of elderly HCC patients remains a challenge worldwide. Recently, studies suggests that the survival outcome of older patients may be comparable to that of younger patients and active treatment may achieve promising rates of local and systemic control in selected patients. Based on above suggestions, we herein offer our experience of a case achieved partial remission by sequential therapy of transarterial chemoembolization after transarterial radioemoblization in elderly HCC patient with multiple metastasis. Further study, maybe regarding a combination of locoregional and systemic treatment, is necessary on how to manage HCC in elderly patients. (J Liver Cancer 2018;18:151-156)

KCI등재

10경동맥화학색전술과 정위절제방사선 병합치료로 완전한 관해를 보인 작은 크기의 간세포암종 1예

저자 : 차준영 ( Jun Young Cha ) , 전백규 ( Baek Gyu Jun ) , 공은정 ( Eun Jeong Gong ) , 서현일 ( Hyun Il Seo ) , 박종규 ( Jong Kyu Park ) , 이상진 ( Sang Jin Lee ) , 김영돈 ( Young Don Kim ) , 한군희 ( Koon Hee Han ) , 정우진 ( Woo Jin Jeong ) , 천갑진 ( Gab Jin Cheon ) , 최원식 ( Won Sik Choi )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 18권 2호 발행 연도 : 2018 페이지 : pp. 157-161 (5 pages)

다운로드

(기관인증 필요)

초록보기

In hepatocellular carcinoma (HCC), surgical resection or local ablation therapy is limited because of severe liver dysfunction or tumor location. Transarterial chemoembolization (TACE) has beed used widely as palliative treatment. Stereotactic Body Radiotherapy (SBRT) is a more recent and effective treatment for early stage HCC. We report a case with small HCC with complete response by TACE combined with SBRT. (J Liver Cancer 2018;18:157-161)

12
권호별 보기
가장 많이 인용된 논문

(자료제공: 네이버학술정보)

가장 많이 인용된 논문
| | | |
1연안해역에서 석유오염물질의 세균학적 분해에 관한 연구

(2006)홍길동 외 1명심리학41회 피인용

다운로드

2미국의 비트코인 규제

(2006)홍길동심리학41회 피인용

다운로드

가장 많이 참고한 논문

(자료제공: 네이버학술정보)

가장 많이 참고한 논문

다운로드

2미국의 비트코인 규제

(2006)홍길동41회 피인용

다운로드

해당 간행물 관심 구독기관

광주여자대학교 조선대학교 순천향대학교 김천대학교 아주대학교
 64
 25
 21
 18
 18
  • 1 광주여자대학교 (64건)
  • 2 조선대학교 (25건)
  • 3 순천향대학교 (21건)
  • 4 김천대학교 (18건)
  • 5 아주대학교 (18건)
  • 6 동남보건대학교 (14건)
  • 7 경동대학교 (13건)
  • 8 백석대학교 (10건)
  • 9 연세대학교 (7건)
  • 10 서울대학교 (6건)

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기